Royalty Report: Drugs, Disease, cardiac – Collection: 301197

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 9

Primary Industries

  • Drugs
  • Disease
  • cardiac
  • Therapeutic
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 301197

License Grant
Licensor grants the Licensee of Japan exclusive rights to NEXLETOL and NEXLIZET tablet development and commercialization in Japan.
License Property
NEXLETOL and NEXLIZE are cost-effective, oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicines.
Field of Use
The field of use is for hypercholesterolemia patients in Japan.  Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, high blood lipids, and hyperlipoproteinemia (elevated levels of lipoproteins in the blood).  High cholesterol can limit blood flow, increasing risk of heart attack or stroke.

IPSCIO Record ID: 257032

License Grant
The Company will grant Japanese Licensee exclusive commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination pill in the European Economic Area and Switzerland (the Territory).   The parties will establish a joint collaboration committee (the “JCC”) to, among other powers and responsibilities, review and guide the implementation and management of development plans of the licensed products in the Territory, review the status of licensed products, approve of Licensee’s request of certain clinical activities, address certain development and manufacturing matters of the licensed products in accordance with the terms of the Agreement, and perform other activities mutually agreed by the Company and Licensee from time to time.
License Property
The bempedoic acid / ezetimibe combination pill, are targeted therapies that have been shown to significantly lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies.

Through the complementary mechanisms of action of inhibition of cholesterol synthesis (bempedoic acid) and inhibition of cholesterol absorption (ezetimibe), the bempedoic acid / ezetimibe combination pill is our lead, non-statin, orally available, once-daily, LDL-C lowering therapy.   Inhibition of ATP Citrate Lyase by bempedoic acid reduces cholesterol biosynthesis.

Field of Use
This agreement pertains to the drug for hypercholesterolemia.  Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, high blood lipids, and hyperlipoproteinemia (elevated levels of lipoproteins in the blood).

IPSCIO Record ID: 294283

License Grant
Licensor grants to the Licensee of Japan an exclusive license in the Territory to use Licensor Know-how and the Licensed Compound to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell Licensed Product(s).

Licensor grants to an exclusive license in the Territory under the Patent Rights to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell the Licensed Compound, solely for use as an active ingredient in Licensed Products and Licensed Products.

License Property
Licensor has Know-How and the Patent Rights relating to the antidyslipidemic compound known as BT16.

BT/6 shall mean any form, including, without limitation, any salt, hydrate, crystalline structure or the like, of the small molecule compound identified by the chemical name B,B-tetramethyl hexadecane-a, (.)-dioic acid.

BT 2000 shall mean the compounds covered by PCT Patent W098/30530 including, without limitation, B, B -tetramethyloctadecanedioic acid.

Licensed Compound shall mean BT16.

The patents include Use of alpha, omega-dicarboxylic acids as fibrinogen sinkers, and, Pharmaceutical compositions containing carboxylic acids and derivatives thereof, and, Methods of administering 3,3,14,14 terramethyl hexadecane 1,16 dioic acid.

BT16 was found to have a potent efficacy of suppressing triglyceride levels in animal and human studies. Further studies demonstrated that it has also insulin-sensitizing properties and the possibility of this compound being developed as a metabolic syndrome therapy in the future has been suggested.

Field of Use
The phase II compound BT16 is r the treatment of dyslipidemia.

Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle.  Dyslipidemia increases the chance of clogged arteries (atherosclerosis) and heart attacks, stroke, or other circulatory concerns, especially in smokers.

Licensee possesses extensive capabilities in the development and commercialization of pharmaceutical products in Japan and in certain countries in Asia.  Licensor is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi interference or RNAi-based therapeutics.

IPSCIO Record ID: 258520

License Grant
The Company granted to Licensee an exclusive license in Japan, with the right to grant sub-licenses, to manufacture and commercialize the Company’s current product.
License Property
The current product is JUXTAPID, a product that contains lomitapide as the sole active ingredient.   Lomitapide is a drug used as a lipid-lowering agent .
Field of Use
The field of use is for the current marketed indication for homozygous familial hypercholesterolemia (HoFH).  Familial hypercholesterolemia is a genetic disorder. It is caused by a defect on chromosome 19. The defect makes the body unable to remove low density lipoprotein (LDL, or bad) cholesterol from the blood.

IPSCIO Record ID: 249742

License Grant
The University grants an exclusive, even as to the University, world-wide license to research, develop, commercialize, make, have made, use, import, offer for sale and sell under the University Existing Patents and New Patents, Licensed Products and Materials in all fields during the Term, and under the Assigned Bristol-Myers Squibb Patents and Assigned BMS Technical Information, the Designated Compounds and University Materials in the Field of Use during the Term.
License Property
The patents include Composition Patents, Combination Patents, and, Universitys Existing and New Patents.

Designated Compound means: BMS-201,038;  prodrugs or metabolites of BMS-201,038, to the extent any such prodrug or metabolite is covered by a composition claim in a Composition Patent; and  stereoisomers, hydrates, anhydrides, solvates, salt forms, or polymorphs of BMS-201,038 or any compounds; furthermore, in the case of a prodrug or metabolite as referred to above, the compound in question will constitute a Designated Compound hereunder only if the making, use or sale of such compound is necessary for or results from the making, use and sale of BMS-210,038 within the Field of Use.

The University completed a Phase II clinical trial of lomitapide for the treatment of patients with called homozygous familial hypercholesterolemia, or HoFH.

Field of Use
Field of Use means:  monotherapy or in combination with other dyslipidemic therapies for treatment of patients with homozygous familial hypercholesterolemia; monotherapy or in combination with other dyslipidemic therapies for treatment of patients with severe hypercholesterolemia of any etiology unable to come within 15% of NCEP LDL cholesterol goal on maximal tolerated oral therapy, as determined by the patient’s prescribing physician; (c) monotherapy or in combination with other dyslipidemic therapies for treatment of patients with severe combined hyperlipidemia of any etiology unable to come within 15% of NCEP non-HDL cholesterol goal on maximal tolerated oral therapy, as determined by the patient’s prescribing physician; and (d) monotherapy or in combination with other dyslipidemic therapies for treatment of patients with severe hypertriglyceridemia unable to reduce TG<1000 on maximal tolerated therapy.

Licensee's lead compound, lomitapide, is a microsomal triglyceride transfer protein inhibitor, or MTP-I, which limits secretion of cholesterol and triglycerides from the intestines and the liver, the main sources of lipids in the body. Licensee is initially developing lomitapide as an oral, once-a-day treatment for patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH.  These patients are at very high risk of experiencing life threatening events at an early age as a result of extremely elevated cholesterol levels in the blood. Licensee believe that lomitapide, either on a stand-alone basis or in combination with other drugs, has the potential to help these patients achieve recommended target levels of low-density lipoprotein cholesterol, or LDL-C.

IPSCIO Record ID: 123666

License Grant
Licensee exercised the right to enter into an exclusive license agreement.  In December 2015, the parties entered into an option agreement to explore a novel approach to develop a drug in the field of hypercholesterolemia.
License Property
The developed drug would be a spleen tyrosine kinase or Syk inhibitors,  a drug in the field of hypercholesterolemia.
Hypercholesterolemia, also called dyslipidemia, is the presence of high levels of cholesterol in the blood.
Field of Use
Licensee is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic diseases and inflammation for patients who currently have limited or no approved treatment options.

IPSCIO Record ID: 233152

License Grant
The Licensor grants to the Cayman Island Licensee and its Affiliates a sole and exclusive  royalty-bearing license, with the right to sublicense, under the Licensor IP and rights in the Product IP, to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize and have Commercialized Compounds and Products in the Field in the Territory.  The License provides exclusive rights to and use of the Licensors patent portfolio of Apo E mimetic peptides and formulations, which have anti-inflammatory properties, in the territory.
License Property
Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides.

Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases.

Field of Use
Field means all diagnostic, therapeutic and prophylactic uses for all indications, except for the diseases of the eye.

IPSCIO Record ID: 249743

License Grant
The German Licensor grants a non-transferable, exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Patent Rights and Know-How, to make, have made, use, sell, offer to sell, import, research, develop, commercialize and otherwise exploit Licensed Compounds and Licensed Products and Improvements. The foregoing license grant includes the right to make reference to all regulatory approvals, data, filings and correspondence, including DMFs contained within the Licensor Know-How.
License Property
Licensor has been engaged in the development of implitapide as an inhibitor of microsomal triglyceride transfer protein.

Licensed Compound means the compound known as Bay 13-9952 and identified as implitapide, and any metabolic precursors, prodrugs, isomers (chiral and otherwise), metabolites, hydrates, anhydrides, solvates, salt forms, free acids or bases, esters, amides, ethers, complexes, conjugates or polymorphs of any compounds.

Field of Use
Licensee is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders.

Lipid disorder means a high blood levels of low-density lipoprotein (LDL) cholesterol, fats called triglycerides, or both.  Lipid disorders, such as high cholesterol, can increase the risk of heart problems, such as heart attack.

IPSCIO Record ID: 300431

License Grant
Each of the Company and Licensee will obtain an exclusive license under certain intellectual property rights of the other party to commercialize Praluent in the United States and outside the United States, respectively.
Licensee of France will transfer to the Company certain assets relating to the commercialization of Praluent in the United States.  The Company, at its sole cost, is solely responsible for the development and commercialization of Praluent in the United States, and Licensee, at its sole cost, is solely responsible for the development and commercialization of Praluent outside of the United States.
License Property
PRALUENT® (alirocumab) is indicated:
– to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.

– as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol (LDL-C).

Field of Use
Praluent® (alirocumab) used in the treatment of high cholesterol.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.